

Denmark

Recent and planned developments in pharmaceutical policies 2017/2018

Special topic: patient involvement in pricing and reimbursement of medicines

CHANGES IN PRICING

Primary setting:

No changes

Hospitals setting:

New set-up with Medicine Council and negotiation of prices for new medicine.

CHANGES IN REIMBURSEMENT

Primary setting:

Some medicine to the treatment of migraine and Parkinson's disease has changed reimbursement status, due to cost and guidelines.

Ongoing reviews of the reimbursement status. Currently ATC-group R03 and ATC-group G.

OTHERS CHANGES

In-patient

- New set-up from 1.1.2017 with Danish medicine council and economic and negotiations in Amgros.
- Recommendation for standard of care 13: 11 yes and 2 no.
- Total products in process: 36

SPECIAL TOPIC: Patient Involvement in Pricing and Reimbursement of Medicines

Out Patient:

The Reimbursement Committee, which advise the Danish Medicines Agency in cases concerning application for general reimbursement of medicines and ongoing reviews of reimbursement status, consist of one member which have to represent patient and consumer interests.

Hospitals medicine:

Danish medicine council have 2 patient representatives in the evaluation of the pharmaceutical.

In each of the therapeutic group a patient representative can participate in the work with the evaluation of the new product or therapeutic areas together with the specialist.

Purpose for involvement of patient in the process:

The patient knowledge and experience can increase the quality in the evaluation of med new medicine or the new therapeutic areas.

The recommendation from The Danish medicine council can secure more focus and relevant for the patients.